Allergic Conjunctivitis
📧 Sign up to get email alerts when something new happens for Allergic Conjunctivitis.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2019-08-02FDA Approved: OLOPATADINE HYDROCHLORIDE OPHTHALMIC SOLUTION — Original Application (Gland Pharma Limited)
FDA approved the original application for olopatadine hydrochloride ophthalmic solution from Gland Pharma Limited, a generic treatment for a…
-
CLINICAL_TRIALS trial_result · 2019-06-19Clinical Trial Update: Evaluation of Prednisolone in a Modified Conjunctival Allergen Challenge Model [Phase 4]
Phase 4 trial evaluating prednisolone in a modified conjunctival allergen challenge model for chronic allergic conjunctivitis; study complet…
-
CLINICAL_TRIALS trial_result · 2019-04-29Clinical Trial Update: Phase II Trial With Subcutaneous Immunotherapy in Patients Sensitized to Phleum Pratense [Phase 2]
Phase II trial of subcutaneous immunotherapy for patients with allergic rhinoconjunctivitis due to Phleum pratense has completed; results po…
-
FDA approval · 2019-04-29FDA Approved: OLOPATADINE HYDROCHLORIDE — Original Application (Alembic Pharmaceuticals Limited)
FDA approved Alembic Pharmaceuticals Limited's olopatadine hydrochloride as an original application (generic) for ophthalmic use in allergic…
-
FDA approval · 2019-04-11FDA Approved: NAPHCON A — Supplemental Application (Alcon Laboratories, Inc.)
FDA approved a supplemental application for NAPHCON A (naphazoline hydrochloride and pheniramine maleate) from Alcon Laboratories, Inc. The …
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2019-04-04FDA Approved: OLOPATADINE HYDROCHLORIDE — Original Application (Allwell Health Inc)
FDA approves Allwell Health Inc's original application for olopatadine hydrochloride, a generic antihistamine for allergic conjunctivitis.
-
FDA approval · 2019-03-25FDA Approved: AZELASTINE HYDROCHLORIDE — Supplemental Application (Amneal Pharmaceuticals LLC)
The FDA has approved a supplemental application for azelastine hydrochloride by Amneal Pharmaceuticals LLC.
-
FDA approval · 2019-03-20FDA Approved: AZELASTINE HYDROCHLORIDE OPHTHALMIC SOLUTION 0.05% — Original Application (Alembic Pharmaceuticals Inc.)
FDA approved a generic azelastine hydrochloride ophthalmic solution 0.05% under an Original Application (ANDA) for Alembic Pharmaceuticals. …
-
FDA approval · 2019-03-18FDA Approved: BEPOTASTINE BESILATE — Original Application (Mylan Pharmaceuticals Inc.)
FDA approved Mylan's original application for bepotastine besilate ophthalmic solution as a generic treatment for allergic conjunctivitis.
-
CLINICAL_TRIALS trial_result · 2019-02-15Clinical Trial Update: Efficacy, Safety and PK of Once or Twice Daily Bilastine (10 or 20 mg) Compared With Placebo in the Symptomatic Treatment of SAR [Phase 2]
Phase 2 trial evaluating the efficacy, safety, and pharmacokinetics of bilastine 10 mg or 20 mg given once or twice daily versus placebo for…
-
CLINICAL_TRIALS trial_result · 2019-02-05Clinical Trial Update: Molekule for Allergic Rhinitis/Asthma [NA]
A Molekule-sponsored clinical trial for asthma and allergic rhinitis (and allergic conjunctivitis) has been terminated.
-
CLINICAL_TRIALS trial_result · 2019-01-29Clinical Trial Update: Diagnostic Equivalence of the Skin Prick Test Tape vs. Conventional Skin PrickTest [NA]
This clinical trial update evaluates whether a tape-based skin prick test provides diagnostically equivalent results to the conventional Ski…
-
FDA approval · 2019-01-28FDA Approved: AZELASTINE HYDROCHLORIDE — Supplemental Application (Apotex Corp.)
The FDA approved a supplemental application for azelastine hydrochloride from Apotex Corp.
-
CLINICAL_TRIALS research · 2019-01-23Clinical Trial Update: China Red Eye Study on Allergic Conjunctivitis
A clinical trial update from China on allergic conjunctivitis sponsored by Sun Yat-sen University; the current trial status is unknown.
-
CLINICAL_TRIALS trial_result · 2019-01-15Clinical Trial Update: Evaluation of the Efficacy of Topical Ophthalmic Steroids in a Modified Conjunctival Allergen Challenge (CAC) Model [Phase 4]
Phase 4 trial update evaluating the efficacy of topical ophthalmic steroids in a modified conjunctival allergen challenge for allergic conju…
-
FDA approval · 2018-12-07FDA Approved: OLOPATADINE HYDROCHLORIDE — Original Application (Alembic Pharmaceuticals Inc.)
FDA approved Alembic Pharmaceuticals' original ANDA for olopatadine hydrochloride, a generic antihistamine indicated for allergic conjunctiv…
-
CLINICAL_TRIALS trial_result · 2018-11-15Clinical Trial Update: Evaluation of the Efficacy of Topical Ophthalmic Steroids in a Modified Conjunctival Allergen Challenge (CAC) Model [Phase 4]
Phase 4 clinical trial evaluating the efficacy of topical ophthalmic steroids in a modified conjunctival allergen challenge model for allerg…
-
FDA approval · 2018-10-17FDA Approved: VISINE ALLERGY EYE RELIEF MULTI-ACTION — Supplemental Application (Kenvue Brands LLC)
The FDA approved a supplemental application for Visine Allergy Eye Relief Multi-Action (Naphazoline hydrochloride and pheniramine maleate) f…
-
CLINICAL_TRIALS withdrawal · 2018-10-02Clinical Trial Update: Clinical Efficacy of PRO-118 Compared With Olopatadine Hydrochloride Ophthalmic Solution in Allergic Conjunctivitis [Phase 3]
Phase 3 clinical trial comparing PRO-118 to olopatadine for allergic conjunctivitis was withdrawn.
-
CLINICAL_TRIALS trial_result · 2018-09-20Clinical Trial Update: Effect of Olopatadine on Allergic Tear Mediators [NA]
A completed clinical trial evaluating the effect of olopatadine on tear mediators in allergic conjunctivitis; results posted in 2018.
-
CLINICAL_TRIALS trial_result · 2018-04-30Clinical Trial Update: OTX-15-002: A Phase 3 Study Evaluating the Safety and Efficacy of OTX-DP for the Treatment of Chronic Allergic Conjunctivitis [Phase 3]
Phase 3 trial for OTX-DP in chronic allergic conjunctivitis completed with posted results.
-
CLINICAL_TRIALS trial_result · 2018-03-29Clinical Trial Update: OTX-14-007: A Phase 3 Study Evaluating the Safety and Efficacy of OTX-DP for the Treatment of Chronic Allergic Conjunctivitis [Phase 3]
Phase 3 trial results for OTX-DP in chronic allergic conjunctivitis were completed and the results were posted in 2018.
-
FDA approval · 2018-03-21FDA Approved: OLOPATADINE HYDROCHLORIDE — Original Application (Rising Pharma Holdings, Inc.)
The FDA approved Rising Pharma Holdings, Inc.'s original ANDA for olopatadine hydrochloride (generic).
-
CLINICAL_TRIALS trial_result · 2018-02-26Clinical Trial Update: Study Evaluating Safety of Ragweed Mix Given by Intralymphatic Node Injections [Phase 1]
A Phase 1 trial evaluating the safety of Ragweed Mix administered by intralymphatic node injections for allergic conjunctivitis and allergic…
-
FDA approval · 2018-02-09FDA Approved: BEPOTASTINE BESILATE — Supplemental Application (Bausch & Lomb Americas Inc.)
FDA approved a supplemental application for BEPOTASTINE BESILATE from Bausch & Lomb Americas Inc.